GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Net Change in Cash

MindBio Therapeutics (XCNQ:MBIO) Net Change in Cash : C$-0.11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

MindBio Therapeutics's Net Change in Cash for the three months ended in Mar. 2024 was C$0.13 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.11 Mil.

MindBio Therapeutics Net Change in Cash Historical Data

The historical data trend for MindBio Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Net Change in Cash Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Net Change in Cash
- 0.75 -0.89

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.04 -0.08 -0.12 0.13

MindBio Therapeutics Net Change in Cash Calculation

MindBio Therapeutics's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.971+0+0.927+0.157
=-0.89

MindBio Therapeutics's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.127+0+0+0
=0.13

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindBio Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Net Change in Cash
Comparable Companies
TSX:APLI TSXV:IOT XCNQ:MESC XCNQ:NOVA XCNQ:BIOV TSXV:RP XCNQ:GLOW TSXV:MRVL TSX:IPCI XCNQ:BRAX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
WF6:Germany
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
Website
https://www.mindbiotherapeutics.com
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

By GuruFocusNews GuruFocusNews • 06-28-2022

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

By Value_Insider Value_Insider • 10-27-2022

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

By sperokesalga sperokesalga • 05-11-2023

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

By sperokesalga sperokesalga • 05-12-2023

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

By PurpleRose PurpleRose • 07-12-2022

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

By sperokesalga sperokesalga • 06-15-2023

Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

By GuruFocusNews GuruFocusNews • 06-21-2022

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

By GuruFocusNews GuruFocusNews • 07-08-2022

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

By Marketwired • 07-31-2023

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

By PurpleRose PurpleRose • 07-13-2022